06.21.24 Abzena, an end-to-end integrated contract and development manufacturing organization (CDMO) for complex biologics and bioconjugates, and Argonaut Manufacturing Services, Inc., a cGMP CDMO serving the biopharmaceutical and diagnostics industries, have partnered to provide a fully integrated drug substance and drug product manufacturing solution for biopharmaceutical organizations—offering a streamlined approach for customers looking to rapidly progress therapies into the clinic, or onward into later-stage commercial manufacturing.
SAN DIEGO, June 20, 2024 /PRNewswire/ -- Abzena, the leading end-to-end integrated contract and development manufacturing organization (CDMO) for complex biologics and bioconjugates, and Argonaut Manufacturing Services, Inc., a cGMP CDMO serving the biopharmaceutical and diagnostics industries, announced a strategic partnership to provide a fully integrated drug substance and drug product manufacturing solution for biopharmaceutical organizations. This alliance offers a streamlined approach for customers looking to rapidly progress therapies into the clinic, or onward into later-stage commercial manufacturing.
SAN DIEGO, Feb. 7, 2024 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, has announced the launch of its new analytical platform, LabZient™. The standardized and automated platform streamlines the assessment and validation of large molecules, which significantly reduces drug development timelines and resource costs.
SAN DIEGO, Dec. 19, 2023 /PRNewswire/ -- Abzena, the leading end-to-end CDMO for complex biologics and bioconjugates, has co-authored a publication with the US Food and Drug Administration (FDA) demonstrating the potential of the MHC Associated Peptide Proteomics (MAPPs) assay as an important method to interrogate immunogenicity risk and help design superior antibody and biologics with a higher chance of a successful outcome in patients.
Abzena, a CDMO for complex biologics and antibody drug conjugates (ADCs), has appointed Thomas Castellano, Chief Financial Officer.
Abzena, an integrated contract development and manufacturing organization (CDMO) for complex biologic molecules and antibody drug conjugates (ADCs), has appointed Sean O’Brien as senior vice president and site head at its San Diego manufacturing facility.
Abzena, an integrated contract development and manufacturing organization (CDMO) for antibody drug conjugates (ADCs) and complex biologic molecules, strengthened its senior leadership team with the appointment of Joe Principe as chief commercial officer, and Matthew Pinkston as vice president, program management.
Abzena, a CDMO specializing in the development and manufacture of antibody-drug conjugates, has laid off 66 employees in San Diego, according to a Worker Adjustment and Retraining Notification (WARN) posted by the state.
Pfizer inks deal to snatch Abzena`s new North Carolina manufacturing site
Abzena, an end-to-end integrated contract development and manufacturing organization (CDMO) for antibody drug conjugates (ADCs) and complex biologic molecules, has appointed Matthew Stober as their new CEO.